ABUS - Arbutus Biopharma Corporation
1.5000 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 1.5100 |
| Open | 1.5200 |
| Bid | 1.4500 x 1400 |
| Ask | 1.5000 x 1300 |
| Day's Range | 1.4750 - 1.5200 |
| 52 Week Range | 0.8200 - 5.1700 |
| Volume | 105,616 |
| Avg. Volume | 486,327 |
| Market Cap | 85.275M |
| Beta (3Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8140 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- Zacks
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -200.00% and -68.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
WARMINSTER, Pa., Nov. 06, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019.
- Simply Wall St.
We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Arbutus to Report Third Quarter 2019 Financial Results
WARMINSTER, Pa., Oct. 30, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
- American City Business Journals
Bucks biopharm firm halts study of potential hepatitis B cure
The study was stopped after two healthy patients developed the condition the therapy was being developed to treat.
- Benzinga
The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) ...
- GlobeNewswire
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
Arbutus Biopharma Corporation (ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor. AB-506 was in a Phase 1a/1b clinical trial for the treatment of chronic hepatitis B (CHB). William H. Collier, President and Chief Executive Officer of Arbutus, stated, “We have observed two cases of acute hepatitis in our Phase 1a 28-day clinical trial in healthy volunteers.
- GlobeNewswire
Arbutus to Participate in Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 26, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Simply Wall St.
Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop?
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- GlobeNewswire
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019. “We are pleased to welcome Dr. Cheng to the Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board of Directors. Dr. Cheng is currently President and Chief Executive Officer of Akero Therapeutics (Nasdaq:AKRO), a biotechnology company focused on the development of transformational treatments for non-alcoholic steatohepatitis (NASH) and other serous metabolic diseases.
- GlobeNewswire
Arbutus to Participate at Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 06, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -31.43% and -20.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating.
- GlobeNewswire
Arbutus to Report Second Quarter 2019 Financial Results
WARMINSTER, Pa., July 29, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced preliminary results from a Phase 1a/1b clinical trial in healthy subjects and two cohorts of chronic hepatitis B (CHB) subjects who received AB-506 monotherapy. A detailed analysis of these Phase 1a/1b preliminary results will be submitted for presentation at a future scientific meeting later this year. William H. Collier, President and Chief Executive Officer of Arbutus, stated, “Preliminary results from this first Phase 1a/1b clinical trial demonstrate that AB-506 is a potent oral capsid inhibitor.
- Insider Monkey
Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Benzinga
The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ...
- GlobeNewswire
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an RNA interference (RNAi) therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (ALNY) (Alnylam), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada. ONPATTRO utilizes Arbutus’s lipid nanoparticle (LNP) technology, which was licensed to Alnylam in November 2012.
- Zacks
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
- GlobeNewswire
Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced it has received regulatory clearance to initiate a Phase 1a/1b clinical trial of AB-729, Arbutus’ subcutaneously-administered RNA interference (RNAi) agent. AB-729 employs a single RNAi trigger that has been shown in preclinical models to span all HBV transcripts, reduce all viral antigens, including hepatitis B surface antigen (HBsAg) expression, and inhibit HBV replication. This RNAi agent uses Arbutus’ proprietary covalently conjugated N-acetylgalactosamine (GalNAc) hepatocyte targeting technology which is expected to allow for once-a-month dosing.
- GlobeNewswire
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of William H. Collier as President and Chief Executive Officer, effective June 24th. Mr. Collier has also been appointed as a member of the Board of Directors of Arbutus, effective June 24th, to fill the vacancy created by the resignation of Mark J. Murray, Ph.D., from the Board of Directors. Dr. Murray will continue to serve as President and Chief Executive Officer and as a member of the Board of Directors until his retirement on June 23rd.
- GlobeNewswire
Arbutus to Participate at JMP Securities Life Sciences Conference
WARMINSTER, Pa., June 13, 2019 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
